John Smither compensation by year
Arcutis Biotherapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2021 | FY2024 |
|---|---|---|
| Salary | $100,000 | $183,333 |
| Bonus | $0 | $0 |
| Stock awards | $755,233 | $1,053,771 |
| Option awards | $5,384,317 | $759,714 |
| Non-equity incentive | $0 | $105,600 |
| Pension and deferred compensation | $0 | $0 |
| All other | $10,752 | $0 |
| Total | $6,250,292 | $2,102,418 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arcutis Biotherapeutics, Inc. DEF 14A filed April 29, 2025, accession 0001787306-25-000069, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Arcutis Biotherapeutics, Inc. filed document, accession 0001787306-25-000069. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 100,000 | $1,393,000 | — |
| RSU | 5,357 | $74,623 | — |
| RSU | 698 | $9,723 | — |
| Option | 50,000 | — | $8.84 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Arcutis Biotherapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Arcutis Biotherapeutics’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| David Topper | Chief Financial Officer | $5,311,203 |
| Todd Franklin Watanabe | President and Chief Executive Officer | $3,689,491 |
| Patrick Burnett | Executive Vice President and Chief Medical Officer | $2,513,050 |
| John Smither · this page | Chief Financial Officer | $2,102,418 |
| L. Todd Edwards | Chief Commercial Officer | $1,965,145 |
| Masaru Matsuda | General Counsel | $1,737,532 |
The full Arcutis Biotherapeutics compensation record
free company briefThis page is one person within Arcutis Biotherapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Arcutis Biotherapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arcutis Biotherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.